This company develops and markets FDA-approved medications, including treatments for asthma, contributing to the management of rare diseases within its therapeutic focus.
0
Orphan Designations
28
FDA Approvals
Latest: LEVETIRACETAM (2015)
0
Active Trials
1
Rare Diseases
across 1 areas
0
News (30d)
Quiet
Prasco Laboratories is a company with 0 orphan drug designations across 1 rare disease, including 28 FDA-approved therapies. 2 active policy bills affect their portfolio.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| asthma | FLUTICASONE PROPIONATE DISKUS | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/1
candidate diseases
0
avg importance: 0
2
affecting portfolio
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/1
candidate diseases
0
avg importance: 0
2
affecting portfolio